Showing results (271-280 of 317) with videos related to

Sort By:
Pageof 32
Haematologica|December 24, 2025
Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s)Sa A Wang, Chi Young Ok, Harrison K Tsai, et al.
Arthritis Care & Research|July 13, 2026
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)Kevin Byram, Heřman Mann, Danielle Hammond, et al.
Blood|November 23, 2018
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenograftsRosalie M Sterner, Reona Sakemura, Michelle J Cox, et al.
American Journal of Hematology|December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survivalOmer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
American Journal of Hematology|December 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patientsNaseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
Blood|October 26, 2021
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformationXiaona You, Fabao Liu, Moritz Binder, et al.
The Journal of Clinical Investigation|November 15, 2024
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemiaPaul Deschamps, Margaux Wacheux, Axel Gosseye, et al.
American Journal of Hematology|July 4, 2020
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantationCihan Heybeli, Meera Sridharan, Hassan B Alkhateeb, et al.
Blood|June 6, 2022
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysisMarie Robin, Liesbeth C de Wreede, Eric Padron, et al.
American Journal of Hematology|January 3, 2022
Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester diseaseJithma P Abeykoon, Terra L Lasho, Surendra Dasari, et al.
Pageof 32